While the safety profile of DPP4 inhibitors predominantly aligns with clinical expectations, the SAVOR-TIMI 53 trial reported that saxagliptin is associated with an increased hazard ratio (1.27) for HF-related hospitalization [6–8]. Here, DPP4 is linked to hydrops fetalis.